Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boeing Co (BA) vs Cassava Sciences Inc (FLNA) Price & Performance

Boeing CoTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Boeing Co vs Cassava Sciences Inc — how do they compare? Boeing Co trades at $219.17 (market cap $171.15B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Boeing Co is far larger — about 3250.1× Cassava Sciences Inc's market cap, and Boeing Co pays a 0.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BAFLNA
Market Cap
$171.15B$52.66M
Volume
7,591,579
Sector
IndustrialsHealth
52-Week High
$252.15$4.64
52-Week Low
$179.12$1.09
Enterprise Value
$197.46B-$33.92M
Dividend Yield
0.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boeing Co

Boeing (BA) trades at $215.51, down 3.05% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 85.18 but improving revenue and net income, reaching $89.46B and $2.24B in 2025, respectively. Recent news highlights potential order wins, including discussions with Riyadh Air for additional 787s, while technical indicators point to support near $209.

Outlook remains cautiously optimistic with a consensus price target of $268.33, implying 24.5% upside, but risks include volatile cash flows, high debt, and ongoing operational challenges. Analyst sentiment is bullish with 66.7% buy ratings, though investors should monitor execution on delivery targets and margin improvements.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boeing Co

The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.

Read more on BA

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA